Tools chosen: polymarket_direct polymarket_related kalshi_related claude_news gdelt_news wikipedia code_execution

Sub-questions (Fermi decomposition)

Planner reasoning

The threshold of 10,000 cases is >4x the 2025 record (~2,300, the highest since 1992), so the base rate is low unless 2026 outbreaks are exploding early. Key research: current CDC 2026 YTD count and trajectory, size/spread of active outbreaks, MMR coverage decline and policy shifts, plus the Polymarket price ladder across other 2026 measles thresholds to build an implied distribution.

# Current state As of the most recent CDC update (~Aug 7, 2026), the U.S. has ~2,465 confirmed measles cases in 2026, already exceeding the full-year 2025 total (2,289, itself the highest since 1992). Reaching the 10,000 threshold requires roughly a 4x increase in the remaining ~5 months of 2026 — a pace well above what current weekly/monthly growth rates support. # Timeline of key events - 2025 (all year): 2,289 confirmed cases nationally, 48 outbreaks, 90% outbreak-associated; highest count since 1992. Driven by West Texas outbreak starting Jan 2025 and later Utah outbreak (from June 2025). (confirmed — CDC/AAP) - 2026-02-12: 910 confirmed cases YTD (confirmed — CDC/claude_news) - 2026-04-02: 1,671 cases YTD (confirmed — CDC) - 2026-06-04: 2,030 cases YTD (confirmed — CDC) - 2026-06-27: CDC adds 30 cases to running total (reported — CIDRAP) - 2026-07-06: 2,170 cases, described as nearing record levels (reported — Medical Daily) - 2026-07-09/10: 2,231 cases; reported as "58 cases from matching 2025 total" (confirmed — Forbes/CIDRAP) - 2026-07-16: 2,260 cases; 5 new cases in Maryland tied to out-of-state travel (confirmed/reported — CDC/Fox5DC) - 2026-07-23/24: 2,318 cases — surpasses full 2025 total, called "35-year high" (confirmed — ABC/NBC/Healio) - 2026-07-26: Seven states (led by South Carolina 670, Utah 522) account for >84% of national cases (confirmed — Medical Daily/NBC) - 2026-07-30: 2,371 cases YTD (confirmed — claude_news synthesis) - 2026-08-07 (approx): 2,465 cases; 94% outbreak-associated (936 from 2026-origin outbreaks, 1,373 from outbreaks starting in 2025); 47 jurisdictions reporting, 38 new outbreaks in 2026 (confirmed — CDC) # Event Will the CDC's official 2026 measles case counter reach ≥10,000 confirmed U.S. cases by year-end 2026? # Outcomes to forecast Yes / No (binary threshold at 10,000 cases) # Kalshi market anchor No direct Kalshi price was returned in research for this exact ticker. The only cross-platform pricing available is **Polymarket: 7.0% YES** (7-day trend +1.2%, 30-day +0.25%; range 5.35–14.95% over 91 days; ~$6.5M volume) — treat this as the best available consensus anchor pending live Kalshi data. A related Kalshi market (avg. measles cases during Trump's term ≥5,000) prices at 34%, but this is a different, cumulative/multi-year metric and not directly comparable. # Sub-question answers 1. **Current 2026 YTD count/date** — ~2,465 confirmed cases as of ~Aug 7, 2026 (CDC via claude_news synthesis), up from 2,371 (Jul 30) and 2,318 (Jul 23-24). 2. **2025 final count / historical max** — 2025 finished at 2,289 cases (CDC/AAP), the highest since 1992 (pre-elimination era); no year since 1992 has reached 10,000 (code_execution base-rate analysis: 0/34 years). 3. **Active outbreaks / elimination status** — Major ongoing outbreaks in South Carolina (670 cases) and Utah (522 cases, originating June 2025, spread statewide including Salt Lake City); together ~half of national cases; 7 states account for 84%+ of total. Elimination status is at risk: continuity of transmission from the 2025 West Texas-origin strain is being tracked; Canada already lost elimination status (Nov 2025) (AAP News). 4. **Month-by-month pace 2025 vs 2026** — 2026 trajectory: 910 (Feb) → 1,671 (Apr) → 2,030 (Jun) → 2,318 (Jul) → 2,465 (Aug), i.e., ~2.7x growth over 6 months, decelerating in recent weeks (~100-150 cases/month recently vs faster spring growth). To hit 10,000 by Dec, growth would need to roughly 4x again in half the remaining time — a sharp acceleration, not continuation of current deceleration. 5. **Vaccination/policy risk** — Kindergarten MMR coverage fell from 95.2% (2019-20) to 92.5% (2024-25), ~286,000 kindergartners under-vaccinated, below ~95% herd-immunity threshold (CDC). No explicit federal ACIP/HHS policy change data surfaced in research; underlying downward vaccination trend is structural and elevates baseline outbreak risk, but no evidence of a discrete 2026 catalyst that would drive a 4x acceleration. 6. **Other market thresholds** — No 1,000/2,500/5,000 threshold Kalshi/Polymarket markets were found directly; illustrative de-vigged ladder modeling (code_execution) estimates P(≥10,000) ≈ 8.8%, roughly consistent with Polymarket's observed 7%. # Key facts (high-confidence, factual) 1. [CDC/claude_news] 2026 YTD ~2,465 cases as of early Aug 2026, already above all of 2025. 2. [CDC/AAP] 2025 total: 2,289 cases — highest since 1992. 3. [CDC] 93% of 2026 cases are unvaccinated/unknown-status individuals; 72% children; ~6% hospitalized; zero deaths reported (as of late July). 4. [Medical Daily/NBC] SC and UT together ~1,192 cases (~48% of national total). 5. [CDC] MMR kindergarten coverage down to 92.5% (2024-25) from 95.2% (2019-20). 6. [code_execution] 0/34 years since 1992 reached 10,000 cases; max historical YoY growth factor 8.07x (2024→2025 anomaly). # Cross-market signals - Kalshi related: "Avg measles cases during Trump's term ≥5,000" priced 34% (different multi-year metric, not directly comparable). - Polymarket (same question): 7% YES, slight upward drift (+1.2% 7d), high volume ($6.5M) — implies genuine liquid consensus this is unlikely but not negligible. - No sportsbook signal available; no additional threshold-ladder markets (1k/2.5k/5k) were located. # Analyst opinions and speculation - CIDRAP/AAP framing emphasizes "record pace" and outbreak persistence (SC, Utah) as upside risk. - code_execution modeling: base-rate view → near-0%; growth-continuation scenarios → wide range (0–50%+) depending on deceleration assumption; blended estimate ~5-10%, aligning with market pricing (~7-9%). - Elimination-status loss narrative (AAP) suggests structural risk is rising but doesn't itself imply a 4x case surge within the year. # Directional lean per outcome - **Yes (≥10,000)**: Supported by record-breaking 2026 pace already exceeding 2025, multiple sustained outbreaks (SC, UT), declining vaccination coverage, and precedent of an 8x YoY jump (2024→2025). Opposed by: current growth is decelerating (~100-150/month recently vs. earlier faster months), no historical precedent since 1992 for reaching this level, and market pricing far below 50%. - **No (<10,000)**: Strongly favored — 34 years of zero precedent, current run-rate implies ~3,000-4,500 total by year-end absent acceleration, and both prediction markets price YES in single digits. # Gaps / unknowns - No live Kalshi YES price was retrieved for this specific ticker (only Polymarket data available as proxy). - No official CDC data more recent than ~early Aug 2026 in research; H2 2026 trajectory (Sep-Dec) unknown. - Uncertain whether SC/UT outbreaks are declining or still expanding; no explicit new-outbreak-onset data for Q4 2026. - No specific ACIP/HHS 2026 policy change details found despite sub-question ask. # Calibration anchors - Polymarket YES price: 7.0% (best available direct anchor). - De-vigged model-implied estimate: ~8.8% (code_execution). - Historical base rate: 0/34 years (1992-2025) ≥10,000 cases. - 2025 record (2,289) is only ~23% of the 10,000 threshold; 2026 YTD (~2,465) already exceeds 2025 total but remains 25% of threshold with ~5 months left.

1. Both forecasts anchor tightly to Polymarket's 7% and the ladder model's 8.8%, but neither questions whether that market is well-calibrated for a rare/fat-tailed epidemic process — outbreak growth is often non-linear (school-year reopening in Sep, holiday travel clustering in Nov-Dec could re-accelerate spread), and the brief itself notes the 2024→2025 YoY jump was 8.07x, showing sudden acceleration is not unprecedented even if rare. 2. Neither forecast explicitly addresses the Q4 seasonal risk: measles transmission historically clusters around school terms and holiday travel, and the brief flags "no explicit new-outbreak-onset data for Q4 2026" as a genuine unknown — both treat the recent deceleration as if it will persist for the remaining 5 months without discounting for this seasonal uncertainty. 3. The gap between the two forecasts (5% vs 8%) is unexplained by any difference in evidence interpretation — both cite identical data points (2,465 cases, 100-150/month pace, 0/34 base rate) yet land at different points without justifying why one sits below and one above the 7-8.8% anchor range; this makes the spread appear arbitrary rather than evidence-driven. 4. Neither forecast stress-tests the scenario where SC/Utah outbreaks are joined by a new large outbreak (e.g., a third state), which given 94% of cases are outbreak-associated and 38 new outbreaks already started in 2026, could compound with the existing 1,192 SC+UT cases faster than simple linear extrapolation suggests. 5. Both forecasts underweight the declining MMR coverage (92.5%, ~286,000 under-vaccinated kindergartners) as a multi-year structural trend that could interact with a single bad-timing outbreak (e.g., in an undervaccinated pocket) to produce a tail event — this is mentioned as "real" by both but not quantified or given explicit tail-scenario probability mass. 6. The Kalshi-specific price was never actually retrieved (only Polymarket proxy), yet both forecasters treat the 7%/8.8% figures as solid anchors without flagging the risk that actual Kalshi pricing could differ meaningfully, especially given thin/no liquidity noted in the brief's gaps section.

4% (medium-high confidence)

Yes: 4% No: 96%

With ~2,465 confirmed cases as of early August and a recent run-rate of only ~100-150 cases/month, reaching 10,000 would require roughly 7,500 additional cases in under five months — a ~15x acceleration over the current pace, not merely a 4x annualized jump. No year since 1992 has come close (0/34), and even a seasonal Q4 re-acceleration from school reopening or holiday travel, plus a plausible new large third-state outbreak, would realistically push the year-end total into the 3,000-5,000 range rather than five figures. The devil's advocate is right that epidemic processes are fat-tailed and that Polymarket's 7% (with no verified Kalshi price) may embed both liquidity noise and the well-documented tendency of retail markets to overprice dramatic tails; the arithmetic gap here is large enough that I sit modestly below the market anchor rather than at it. I retain non-trivial mass for the tail given falling MMR coverage (92.5%), 94% outbreak-associated cases, and uncertainty about H2 outbreak onset, but the required acceleration is far beyond anything observed in the data window.

Total pipeline time: 307.0s